These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21792639)

  • 1. The role of atherosclerosis imaging in redefining normal and abnormal cholesterol values, and risk reduction in primary prevention statin trials.
    Hecht HS
    Curr Atheroscler Rep; 2011 Oct; 13(5):422-30. PubMed ID: 21792639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting.
    Natarajan P; Young R; Stitziel NO; Padmanabhan S; Baber U; Mehran R; Sartori S; Fuster V; Reilly DF; Butterworth A; Rader DJ; Ford I; Sattar N; Kathiresan S
    Circulation; 2017 May; 135(22):2091-2101. PubMed ID: 28223407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
    JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study.
    Mortensen MB; Fuster V; Muntendam P; Mehran R; Baber U; Sartori S; Falk E
    J Am Coll Cardiol; 2016 Aug; 68(9):881-91. PubMed ID: 27561760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
    Pursnani A; Massaro JM; D'Agostino RB; O'Donnell CJ; Hoffmann U
    JAMA; 2015 Jul; 314(2):134-41. PubMed ID: 26172893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary artery calcium and carotid artery intima-media thickness for the prediction of stroke and benefit from statins.
    Osawa K; Trejo MEP; Nakanishi R; McClelland RL; Blaha MJ; Blankstein R; McEvoy JW; Ceponiene I; Stein JH; Sacco RL; Polak JF; Budoff MJ
    Eur J Prev Cardiol; 2018 Dec; 25(18):1980-1987. PubMed ID: 30183342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practice.
    Jarauta E; Mateo-Gallego R; Bea AM; Crespo M; Ballester A; Rubio MV; Baila-Rueda L; Calmarza P; Cenarro A; de Groot E; Civeira F
    J Clin Lipidol; 2014; 8(4):373-80. PubMed ID: 25110218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.
    Waheed S; Pollack S; Roth M; Reichek N; Guerci A; Cao JJ
    Atherosclerosis; 2016 Dec; 255():193-199. PubMed ID: 27693004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary artery calcium: utilization for primary prevention of CHD.
    Hecht HS
    Curr Cardiol Rep; 2011 Dec; 13(6):465-74. PubMed ID: 21892753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Flueckiger P; Qureshi W; Michos ED; Blaha M; Burke G; Sandfort V; Herrington D; Yeboah J
    Clin Cardiol; 2017 Mar; 40(3):163-169. PubMed ID: 27859433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is carotid artery evaluation necessary for primary prevention in asymptomatic high-risk patients without atherosclerotic cardiovascular disease?
    Kim G; Youn HJ; Choi YS; Jung HO; Chung WS; Kim CM
    Clin Interv Aging; 2015; 10():1111-9. PubMed ID: 26185430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rosuvastatin in the management of dyslipidemia.
    Rubba P; Marotta G; Gentile M
    Vasc Health Risk Manag; 2009; 5(1):343-52. PubMed ID: 19436657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclinical atherosclerosis imaging comes of age: coronary artery calcium in primary prevention.
    Hecht HS
    Curr Opin Cardiol; 2012 Sep; 27(5):508-14. PubMed ID: 22872131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of serum LDL particle concentration with carotid intima-media thickness and coronary artery calcification.
    Zaid M; Miura K; Fujiyoshi A; Abbott RD; Hisamatsu T; Kadota A; Arima H; Kadowaki S; Torii S; Miyagawa N; Suzuki S; Takashima N; Ohkubo T; Sekikawa A; Maegawa H; Horie M; Nakamura Y; Okamura T; Ueshima H;
    J Clin Lipidol; 2016; 10(5):1195-1202.e1. PubMed ID: 27678437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
    Ikeda K; Takahashi T; Yamada H; Matsui K; Sawada T; Nakamura T; Matsubara H;
    Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Benefit.
    Cesena FHY; Laurinavicius AG; Valente VA; Conceição RD; Nasir K; Santos RD; Bittencourt MS
    Am J Cardiol; 2018 Jun; 121(11):1315-1320. PubMed ID: 29605080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.